マルチプレックスアッセイの世界市場規模、シェア、成長分析、製品タイプ別、技術別、用途別-産業予測、2024～2031年

マルチプレックスアッセイの世界市場規模は2022年に約20億5,000万米ドルと評価され、2023年の23億5,000万米ドルから上昇し、予測期間（2024～2031年）のCAGRは14.77%で、2031年には70億8,000万米ドルに達すると予測されています。

世界のマルチプレックスアッセイ市場を牽引する主要要因は、感染症や慢性疾患の有病率の増加、シングルプレックスや従来のアッセイに対するマルチプレックスアッセイの主要利点、コンパニオン診断におけるマルチプレックスアッセイの使用の増加、早期診断に対する意識の高まりです。

現在の医薬品承認シナリオから予測すると、コンパニオン診断薬は近い将来大幅に拡大すると予想されます。例えば、FDAは2021年8月、抗PD-1免疫療法の効果が期待できる患者のdMMR固形腫瘍を見つけるためのコンパニオン診断薬の販売をRocheに許可しました。したがって、コンパニオン診断薬の拡大により、世界市場の成長は大きく促進される可能性があります。早期診断は、生存率が3倍上昇するがんを含む多くの慢性疾患において、患者のQOLを高めることができます。早期発見はまた、長期にわたる疾病のコストを削減し、利用可能な治療法の範囲を広げることができます。

2021年7月にAvalere誌に掲載された報告によると、病気が他の身体部位に広がり生存の可能性が低下するまでに、非小細胞肺がん、胃がん、膵臓がんの患者の36％から53％がステージ4のがんと診断されるといいます。非小細胞肺がん、胃がん、膵臓がんを早期発見できれば、5年生存率は2倍になります。このような違いにより、早期診断の価値に対する認識が高まっており、予測期間を通じて市場の成長に大きな影響を与える可能性があります。分子・タンパク質診断におけるバイオマーカーの検証の増加は、自動化システムやハイスループット試験に対する需要の高まりと相まって、市場拡大の機会をさらにもたらすであろう。

複数のバイオマーカー分析は、神経疾患、自己免疫疾患、がんの研究に数多く応用されています。非常に多くのバイオマーカーが発見され検証されていることから、新たな診断法が開発される可能性が高いです。マルチプレックス試験は、バイオマーカーを同定するためにタンパク質を定量的に評価するために使用できます。これらのアッセイでは、統計的に有意な量のサンプルと対照を用いて、いくつかの潜在的なタンパク質バイオマーカーを評価することができます。その結果、バイオマーカーバリデーションにマルチプレックスアッセイを適用することで、信頼できるデータを提供する効率とスピードが向上し、短期的な市場拡大が期待できます。

目次

エグゼクティブサマリー

• 市場概要
• 隆盛と衰退

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模の推定
• 市場の危機と限界

親市場の分析

• 市場概要
• 市場規模
• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題

主要市場の考察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 貿易分析
• スタートアップ分析
• 原材料の分析
• イノベーションマトリクス
• パイプライン製品の分析
• マクロ経済指標
• 主要投資の分析
• 主要成功要因
• 競合の程度

市場力学と展望

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• 規制情勢
• ポーターの分析
• 将来の混乱についての特別な考察

マルチプレックスアッセイの世界市場：製品別

• 市場概要
• 消耗品
• 機器とソフトウェア

マルチプレックスアッセイの世界市場：タイプ別

• 市場概要
• タンパク質マルチプレックスアッセイ
• 核酸マルチプレックスアッセイ
• 細胞ベースのマルチプレックスアッセイ

マルチプレックスアッセイの世界市場：技術別

• 市場概要
• フローサイトメトリー
• 蛍光検出
• 発光
• マルチプレックスリアルタイムPCR
• その他

マルチプレックスアッセイの世界市場：用途別

• 市場概要
• 研究開発
• 臨床診断

マルチプレックスアッセイの世界市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • その他の欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2021年）
• 主要市場企業が採用した戦略
• 主要成功戦略
• 市場における最近の活動
• 主要企業の市場シェア（2021年）

主要企業プロファイル

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Illumina, Inc.
• Agilent Technologies, Inc.
• Luminex Corporation
• Merck KGaA
• QIAGEN N.V.
• Roche Diagnostics
• Randox Laboratories Ltd.
• Bio-Techne Corporation
• Abcam plc
• GenScript Biotech Corporation
• Mesoscale Discovery, LLC
• Seegene Inc.
• Becton, Dickinson and Company
• Fluidigm Corporation
• Meso Scale Diagnostics, LLC
• PerkinElmer, Inc.
• Siemens Healthineers AG
• Biocartis NV

Global Multiplex Assay Market size was valued at around 2.05 billion in 2022 and is expected to rise from USD 2.35 billion in 2023 to reach a value of USD 7.08 Billion by 2031, at a CAGR of 14.77 % over the forecast period (2024-2031).

The primary factors driving the global multiplex assay market are the increasing prevalence of infectious and chronic diseases, the key benefits of multiplex assays over single plex and conventional assays, the growth of multiplex assay use in companion diagnostics, and the rising awareness of early diagnosis.

Predicted on current drug approval scenarios, companion diagnostics is expected to significantly expand in the near future. For example, the FDA authorized Roche to sell companion diagnostics in August 2021 to find dMMR solid tumors in patients who would benefit from anti-PD-1 immunotherapy. Therefore, the growth of the global market can be significantly aided by the expansion of companion diagnostics. Early diagnosis can enhance a patient's quality of life in many chronic diseases, including cancer, where there is a threefold increase in survival rate. Early detection can also reduce the cost of long-term illnesses and increase the spectrum of accessible therapies.

An report published in Avalere in July 2021 states that by the time the disease has spread to other body areas and decreased the likelihood of survival, between 36% and 53% of patients with non-small cell lung cancer, stomach cancer, and pancreatic cancer are diagnosed with stage 4 cancer. If non-small-cell lung cancer, stomach cancer, and pancreatic cancer are detected in their early stages, the 5-year survival rate can double. These differences are increasing awareness of the value of early disease diagnosis and could have a major impact on market growth throughout the projected period of time. The increasing validation of biomarkers in molecular and protein diagnostics, coupled with the growing demand for automated systems and high-throughput tests, will further present opportunities for market expansion.

Numerous applications of multiple biomarker analysis can be found in the research of neurological diseases, autoimmune diseases, and cancer. With so many biomarkers being discovered and validated, it is highly likely that new diagnoses will be developed. A multiplex test can be used to assess proteins quantitatively in order to identify biomarkers. These assays allow evaluation of several potential protein biomarkers using statistically significant quantities of samples and controls. As a result, the application of multiplex assays in biomarker validation improves the efficiency and speed at which reliable data may be delivered, thereby fostering short-term market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiplex Assay Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiplex Assay Market Segmental Analysis

The global multiplex assay market is segmented based on product, type, technology, application, process and region. Based on product the market is segmented into consumables, instruments and software. In terms of type, the market is segmented into protein multiplex assays, planar protein assays, bead-based protein assays, nucleic acid multiplex assays, planar protein assays, bead-based protein assays, and cell-based multiplex assays. Further classification of technology segments include flow cytometry, fluorescence detection, luminescence, multiplex real-time PCR, and other technologies. Based on application the market is segmented into research & development and clinical diagnostics. Based on end-users the market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, research & academic institutes, and other end-users. Based on region the global multiplex assay market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Multiplex Assay Market

Multiplex assay demand is being driven by the increasing need for personalized medication. Multiple biomarkers can be measured simultaneously with these assays, improving patient classification and enabling more individualized treatment choices.

Restraints in the Global Multiplex Assay Market

Multiplex assays' acceptance may be constrained by the regulatory issues they raise. Regulatory clearance for these assays is necessary, and it can be expensive and time-consuming.

Market Trends of the Global Multiplex Assay Market

Growing use of multiplex immunoassays: Because multiplex immunoassays can test many proteins in a single sample, there is a growing demand for these assays. Drug discovery, diagnostic testing, and biomarker identification all make extensive use of these assays.

Increasing use of microarrays: Because microarray technology can assess numerous analytes at once, it is becoming more and more popular in the multiplex assay market. Drug discovery, proteomics, and genomes all make extensive use of microarrays.

Next-generation sequencing (NGS) technology development: Because NGS technologies can sequence a large number of genes or DNA fragments at once, they are being used more often in multiplex experiments. Personalized medicine, diagnostic testing, and genomics research all make extensive use of NGS technologies.

Growing requirement for point-of-care testing (POCT): The need for quick and precise diagnostic testing is driving the demand for POCT. Because multiplex assays allow for the simultaneous detection of numerous analytes in a single sample, they are a good fit for point-of-care testing.

Precision medicine is becoming more and more popular. It is a new area that focuses on tailoring medical care to a patient's genetic composition, lifestyle, and surroundings. Precision medicine benefits greatly from multiplex assays since they allow for the evaluation of several biomarkers in one sample, resulting in individualized treatment options.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Multiplex Assay Market by Product

• Market Overview
• Consumables
• Instruments and Software

Global Multiplex Assay Market by Type

• Market Overview
• Protein Multiplex Assays
• Nucleic Acid Multiplex Assays
• Cell-based Multiplex Assays

Global Multiplex Assay Market by Technology

• Market Overview
• Flow Cytometry
• Fluorescence Detection
• Luminescence
• Multiplex Real-time PCR
• and Other Technologies

Global Multiplex Assay Market by Application

• Market Overview
• Research & Development
• and Clinical Diagnostics

Global Multiplex Assay Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luminex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abcam plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mesoscale Discovery, LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seegene Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fluidigm Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meso Scale Diagnostics, LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocartis NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments